Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of "Buy" from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have earned a consensus recommendation of "Buy" from the nine analysts that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $13.13.

A number of brokerages have recently issued reports on CMPX. Piper Sandler started coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price target for the company. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Guggenheim cut their target price on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 9th. HC Wainwright reissued a "buy" rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Finally, Wedbush reaffirmed an "outperform" rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st.

Insider Activity at Compass Therapeutics

In related news, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This trade represents a 2,000.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is owned by corporate insiders.

Institutional Trading of Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its holdings in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares during the period. Strs Ohio bought a new position in Compass Therapeutics in the 1st quarter worth $34,000. Independent Advisor Alliance acquired a new position in shares of Compass Therapeutics during the 4th quarter worth about $26,000. BNP Paribas Financial Markets bought a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $27,000. Finally, Mariner LLC acquired a new position in shares of Compass Therapeutics during the fourth quarter valued at about $30,000. Institutional investors own 68.43% of the company's stock.

Compass Therapeutics Price Performance

NASDAQ:CMPX traded up $0.19 during trading hours on Monday, hitting $2.38. The company's stock had a trading volume of 765,396 shares, compared to its average volume of 952,958. The stock has a fifty day simple moving average of $2.05 and a 200-day simple moving average of $2.21. The company has a market capitalization of $329.11 million, a P/E ratio of -5.80 and a beta of 1.41. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). On average, equities analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.